Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
AssigneeScantibodies Laboratory, Inc.
InventorThomas L. Cantor
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism. One determines and monitors the level of parathyroid hormone agonist and parathyroid hormone antagonist in the renal patient. The parathyroid hormone suppressing therapeutic is administered to the patient so as to minimize the level of parathyroid hormone antagonist.
Claims39
A method for monitoring and guiding therapeutic suppression of parathyroid hormone in a renal patient having secondary hyperparathyroidism, said method comprising:
- a) obtaining a sample of blood, serum or plasma from said renal patient;
- b) determining and monitoring the level of a parathyroid hormone (PTH) agonist in said sample,
- wherein said agonist comprises a contiguous segment of human PTH having the amino acid sequence SEQ ID NO:1,
- wherein said segment starts at position 1 of human PTH, and ends at any position from position 34 through position 84 of human PTH;
- c) determining and monitoring the level of a PTH antagonist in said sample,
- wherein said antagonist comprises a contiguous portion of human PTH having the amino acid sequence SEQ ID NO:1,
- wherein said portion starts at any position from position 2 through position 33 of human PTH, ends at any position from position 35 through position 84 of human PTH, and has a minimal length of three amino acid residues;
- and
- d) administering a therapeutic that suppresses PTH agonist to the patient whereby the amount of therapeutic administered is adjusted such that PTH agonist levels are decreased and the level of PTH antagonist is minimized.
A method for monitoring and guiding therapeutic suppression of parathyroid hormone having the sequence set forth in SEQ ID NO:1 in a renal patient having secondary hyperparathyroidism, said method comprising:
- a) obtaining a sample of blood, serum or plasma from the patient;
- b) determining and monitoring the level of a parathyroid hormone (PTH) antagonist in the sample,
- wherein said antagonist comprises a contiguous portion of human PTH having the amino acid sequence SEQ ID NO:1,
- wherein said portion starts at any position from position 2 through position 33 of human PTH, ends at any position from position 35 through position 84 of human PTH, and has a minimal length of three amino acid residues;
- and
- c) administering to the patient a therapeutic capable of suppressing a PTH agonist, whereby the amount of therapeutic administered is adjusted such that the level of PTH antagonist is minimized in the patient.
A method for determining an appropriate dosage of a therapeutic for suppression of parathyroid hormone having the sequence set forth in SEQ ID NO:1 in a renal patient having secondary hyperparathyroidism, said method comprising:
- a) administering a therapeutic capable of suppressing PTH to said renal patient;
- b) obtaining a sample of blood, plasma or serum from said renal patient;
- c) determining the level of a PTH antagonist in the sample,
- wherein said antagonist comprises a contiguous portion of human PTH having the amino acid sequence SEQ ID NO:1,
- wherein said portion starts at any position from position 2 through position 33 of human PTH, ends at any position from position 35 through position 84 of human PTH, and has a minimal length of three amino acid residues;
- and
- d) adjusting the dosage of said therapeutic up or down;
- e) monitoring the level of said PTH antagonist in said patient by obtaining an additional sample of blood, plasma, or serum from the patient and measuring the level of said PTH antagonist in said sample;
- and
- f) further adjusting the dosage of said therapeutic up or down until the level of said PTH antagonist is minimized.
Dependencies are inferred from the claim text.